Who’s Going to ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

736 companies and 1,135 speakers at ESMO 2026, a ~37,000-person congress of oncologists, cancer researchers and oncology industry. As of Sep 29, 2026.

Showing 1–1 of 736 organizations

Organization	ESMO 2026 Attendance
Gustave Roussy Villejuif, France
gustaveroussy.fr Cancer centre & hospital Comprehensive cancer centre in Villejuif, near Paris, France, affiliated with Paris-Saclay University.	Keynote Fri Oct 23 11:30–11:38 ESMO Presidential address ESMO 2026 Opening session Talk Fri Oct 23 14:30–14:50 Therapeutic approaches in advanced/recurrent EC beyond CPIs and ADCs Update on the mangement of endometrial cancer in the era of molecular classification Gynaecological cancers Talk Fri Oct 23 16:15–16:35 Novel AR targeted therapies Emerging therapeutic strategies in advanced prostate cancer Genitourinary cancers Abstract Fri Oct 23 16:25–16:37 Invited Discussant 1243RO and 1244RO Rapid oral 1: Gynaecological cancers Gynaecological cancers Talk Fri Oct 23 16:30–16:45 Basket trials: When is enough, enough? Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Talk Sat Oct 24 08:30–08:50 Enhance inclusiveness and patient accrual for clinical trials Solutions to overcome barriers of access to clinical trials Talk Sat Oct 24 08:30–08:50 Presentation by Expert Sequencing systemic therapies for advanced urothelial cancer Genitourinary cancers Chair Sat Oct 24 08:30–10:00 Solutions to overcome barriers of access to clinical trials with Netherlands Cancer Institute Abstract Sat Oct 24 08:35–08:40 2719RO - FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem) Rapid oral 1: NSCLC, metastatic Lung & thoracic cancers Talk Sat Oct 24 08:40–08:50 Welcome from ESMO EONS Opening session Nursing & supportive care Talk Sat Oct 24 09:10–09:30 Systemic approach Challenges in the treatment approach of HPV-related head and neck cancers Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 09:15–09:25 LBA26 - Short-term preoperative durvalumab for stage I TNBC: first results from the phase II UNLOCK 14 - POP-DURVA trial Proffered paper 2: Breast cancer, early and advanced stage Breast cancer Abstract Sat Oct 24 09:45–09:55 Invited Discussant 1457O, 1458O and 1459O Proffered Paper: Haematological malignancies Haematological malignancies Abstract Sat Oct 24 10:15–10:20 LBA16 - VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2) Rapid oral 1: Breast cancer, advanced stage Breast cancer Talk Sat Oct 24 11:30–11:37 Table 1 Mentor the Mentor session Chair Sat Oct 24 12:00–12:50 ESMO-EACR: What oncologists should know about molecular oncology with University of Turin, VIB Biomarkers & precision oncology Chair Sat Oct 24 12:00–12:50 What oncologists should know about managing toxicities of novel therapies with Samsung Medical Center, Hospital Clínic de Barcelona Nursing & supportive care Talk Sat Oct 24 12:15–12:30 Bispecifics What oncologists should know about managing toxicities of novel therapies Nursing & supportive care Talk Sat Oct 24 12:15–12:30 DNA repair ESMO-EACR: What oncologists should know about molecular oncology Biomarkers & precision oncology Satellite Sat Oct 24 14:05–14:17 Nuclear Medicine: partner for the Prostate Cancer journey Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future Genitourinary cancers Chair Sat Oct 24 14:45–16:15 Emerging toxicities induced by antibody-drug conjugates with Odense University Hospital Nursing & supportive care Talk Sat Oct 24 14:45–15:10 Pulmonary toxicities Emerging toxicities induced by antibody-drug conjugates Nursing & supportive care Talk Sat Oct 24 15:00–15:15 Pheochromocytoma and paraganglioma Emerging therapies in endocrine and neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 15:15–15:35 How will new technologies contribute to precision medicine? YO Lecture: What to expect from precision medicine in the next decade Biomarkers & precision oncology Talk Sat Oct 24 15:20–15:35 View of the interventional radiologist Management of locally advanced HCC Gastrointestinal cancers Talk Sat Oct 24 15:45–16:05 NUT carcinomas, salivary gland cancers and pulmonary blastomas Updates on rare thoracic tumours Lung & thoracic cancers Talk Sat Oct 24 15:45–16:05 What to do after optimal neoadjuvant therapy? Optimising treatment for triple negative early breast cancer Breast cancer Chair Sat Oct 24 16:30–18:15 Presidential Symposium I Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sat Oct 24 18:30–20:00 Ipsen - Treatment decisions that shape the journey in RCC and NETs with University Hospital Erlangen Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:30–18:33 Welcome Ipsen - Treatment decisions that shape the journey in RCC and NETs Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:33–18:43 Sequencing in an ever-changing landscape (RCC and NETs) Ipsen - Treatment decisions that shape the journey in RCC and NETs · with University Hospital Erlangen Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:43–19:23 Navigating the RCC treatment journey Ipsen - Treatment decisions that shape the journey in RCC and NETs · with City of Hope, Arthur Child Comprehensive Cancer Centre Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 08:30–08:35 Presentation of case/condition Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations Chair Sun Oct 25 08:30–10:00 Rapid oral 2: NSCLC, metastatic with Hospital Universitario 12 de Octubre, Centre Léon Bérard Lung & thoracic cancers Chair Sun Oct 25 08:30–10:00 Rapid oral: Developmental therapeutic with START Center for Cancer Care, University of Oxford Chair Sun Oct 25 08:30–09:45 Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations with Heidelberg University Hospital Abstract Sun Oct 25 08:35–08:40 4245RO - Complementary roles of Liquid Biopsy and Imaging in Assessing Tumor Burden in Metastatic Cancer Rapid oral 1: Basic science and translational research Biomarkers & precision oncology Abstract Sun Oct 25 08:45–08:57 Invited Discussant 1006RO, LBA33 and 1007RO Rapid oral: Developmental therapeutic Talk Sun Oct 25 08:55–09:15 Implementation science (incl. Federated learning) Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations Abstract Sun Oct 25 08:57–09:02 4246RO - Microbiome Toposcore Dynamics Following Fecal Microbiota Transplantation in Immuno-Oncology: A Multi-Cohort Longitudinal Analysis Rapid oral 1: Basic science and translational research Biomarkers & precision oncology Abstract Sun Oct 25 09:29–09:44 Invited Discussant 2618RO, 2652RO and 2680RO Rapid oral 2: NSCLC, metastatic Lung & thoracic cancers Chair Sun Oct 25 10:15–11:45 AI in cancer care: Transforming treatment, navigating challenges with Memorial Sloan Kettering Cancer Center Chair Sun Oct 25 10:15–11:45 ESMO-ASCO: The evolving definition of the modern oncologist with Dana-Farber Cancer Institute Chair Sun Oct 25 10:15–11:45 Emerging new systemic therapies for RCC with Ghent University Hospital Genitourinary cancers Talk Sun Oct 25 10:15–10:35 Novel HIF2a targeted agents and combination strategies Emerging new systemic therapies for RCC Genitourinary cancers Talk Sun Oct 25 10:45–11:00 AI for drug development AI in cancer care: Transforming treatment, navigating challenges Satellite Sun Oct 25 13:05–13:15 Building Bridges in the Management of CSCC Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more Melanoma & skin cancers Satellite Sun Oct 25 13:10–13:40 Addressing myths in first treatment choice to optimise outcomes and patient wellbeing in mHSPC Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer · with Cliniques universitaires Saint-Luc Genitourinary cancers Satellite Sun Oct 25 13:15–13:35 Resectable or Not: Navigating the Gray Zones in Advanced CSCC Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more Melanoma & skin cancers Satellite Sun Oct 25 13:35–13:50 Defining High-risk CSCC: Identifying Patients Who Need More Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more Melanoma & skin cancers Satellite Sun Oct 25 13:40–13:45 Audience Q&A: Advanced prostate cancer Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer · with Hospital Clínico San Carlos, Cliniques universitaires Saint-Luc Genitourinary cancers Talk Sun Oct 25 13:45–14:00 Rewriting the patient voice with large language models Digital health, data and innovation Satellite Sun Oct 25 13:50–14:20 Timing and Selection of Systemic Therapy in Resectable CSCC Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more Melanoma & skin cancers Satellite Sun Oct 25 14:20–14:30 Audience Q&A Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more Melanoma & skin cancers Chair Sun Oct 25 14:45–16:25 Proffered paper: Prevention, early detection and intervention with Memorial Sloan Kettering Cancer Center Talk Sun Oct 25 15:10–15:30 Neoadjuvant therapy: A global prescription for cure More cures in early melanoma Melanoma & skin cancers Abstract Sun Oct 25 15:44–15:49 1538RO - First Interim Safety analysis of GORTEC 2024-03 IDEAL: randomized phase II trial of induction treatment anti–PD-1 pucotenlimab (HX008) plus EGFR-ADC (becotatug vedotin (MRG003) versus EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma Rapid oral: Head and neck cancer Sarcoma, CNS, head & neck and rare cancers Abstract Sun Oct 25 15:44–15:49 3594RO - Feasibility and reproducibility of PD-L1 assessment within CARE1: a phase III, randomized, biomarker-driven pragmatic trial to optimize first line treatment in patients (pts) with metastatic clear-cell renal cell carcinoma (mRCC) Rapid oral 2: Genitourinary tumours, renal and urothelial Genitourinary cancers Abstract Sun Oct 25 16:05–16:15 Invited Discussant 3440O and 3441O Proffered paper: Prevention, early detection and intervention Talk Sun Oct 25 16:30–16:55 Individual cancer risk assessment: A critical appraisal Pillars of personalised cancer prevention: The breast cancer case Breast cancer Abstract Sun Oct 25 16:42–16:54 Invited Discussant LBA5 Presidential Symposium II Lung & thoracic cancersGastrointestinal cancers Talk Mon Oct 26 08:30–08:50 ESMO’s Framework for the evaluation of cancer early detection biomarkers in bodily fluids Early detection and prevention of cancer Chair Mon Oct 26 08:30–10:00 Early detection and prevention of cancer with Winship Cancer Institute of Emory University Chair Mon Oct 26 08:30–10:00 Navigating the wave of new therapies in gynaecologic cancers with University Hospitals Leuven Gynaecological cancers Abstract Mon Oct 26 08:40–08:50 LBA92 - HOPE: phase III randomized trial of a personalized digital supportive-care pathway (DP) for endocrine therapy (ET) symptoms in early breast cancer (BC) Proffered paper: Supportive and palliative care Nursing & supportive care Talk Mon Oct 26 09:10–09:30 ESMO guidance on endpoints, study designs, and expected magnitude of clinical benefit for the pharmacological prevention of cancer Early detection and prevention of cancer Abstract Mon Oct 26 09:38–09:50 Invited Discussant 3084O, 3893O and 3894O Proffered paper: Supportive and palliative care Nursing & supportive care Chair Mon Oct 26 10:15–11:45 Addressing the risk of second primary cancers with Queen Elizabeth Hospital Nursing & supportive care Chair Mon Oct 26 13:00–14:30 ESMO Fellowship Programme: Educational opportunities for young oncologists with Institut Strauss, Hospital Clínic de Barcelona Talk Mon Oct 26 13:25–13:35 From emerging oncologist to independent investigator: A personal journey ESMO Fellowship Programme: Educational opportunities for young oncologists Chair Mon Oct 26 14:45–15:45 ESMO-CSCO: Navigating the development pathways of cancer therapeutics -From China to the world with Guangdong Provincial People's Hospital Chair Mon Oct 26 14:45–16:15 Proffered paper: Non-metastatic NSCLC and other thoracic malignancies with Erasmus MC Lung & thoracic cancers Abstract Mon Oct 26 14:55–15:00 3137RO - Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Rapid oral 2: Gastrointestinal tumour, upper digestive Gastrointestinal cancers Talk Mon Oct 26 15:10–15:25 How to simplify the algorithm of treatment of rare endocrine tumors Endocrine tumours at a glance Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 15:12–15:17 3884RO - Lung Cancer Prevention in Patients with Severe Mental Illness: A Real-World Cohort Experience from the INTERCEPTION-Lung Precision Prevention Program Rapid oral: Prevention, early detection and intervention Abstract Mon Oct 26 15:53–16:05 Invited Discussant LBA64, 2519O and 2511O Proffered paper: Non-metastatic NSCLC and other thoracic malignancies Lung & thoracic cancers Chair Mon Oct 26 16:30–17:45 Alleviating total suffering in patients with advanced cancer: It’s time for interdisciplinary interventions with Aston University Nursing & supportive care Chair Mon Oct 26 16:30–18:00 IO-based systemic therapy in head and neck cancers with National Centre for Oncological Hadrontherapy (CNAO) Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 16:30–16:35 Presentation of case/condition Alleviating total suffering in patients with advanced cancer: It’s time for interdisciplinary interventions Nursing & supportive care Abstract Mon Oct 26 16:42–16:54 Invited Discussant LBA9 Presidential Symposium III Gynaecological cancersSarcoma, CNS, head & neck and rare cancers Chair Tue Oct 27 09:00–13:00 Scientific Congress Highlights 2 with Hospital Clínic de Barcelona Talk Tue Oct 27 12:40–13:00 Prevention, early detection and intervention Scientific Congress Highlights 2

Organization

ESMO 2026 Attendance

Gustave Roussy

Villejuif, France

gustaveroussy.fr

Cancer centre & hospital

Comprehensive cancer centre in Villejuif, near Paris, France, affiliated with Paris-Saclay University.

Keynote

Fri Oct 23
11:30–11:38

ESMO Presidential address

ESMO 2026 Opening session

Talk

Fri Oct 23
14:30–14:50

Therapeutic approaches in advanced/recurrent EC beyond CPIs and ADCs

Update on the mangement of endometrial cancer in the era of molecular classification

Gynaecological cancers

Talk

Fri Oct 23
16:15–16:35

Novel AR targeted therapies

Emerging therapeutic strategies in advanced prostate cancer

Genitourinary cancers

Abstract

Fri Oct 23
16:25–16:37

Invited Discussant 1243RO and 1244RO

Rapid oral 1: Gynaecological cancers

Gynaecological cancers

Talk

Fri Oct 23
16:30–16:45

Basket trials: When is enough, enough?

Raising the bar for tumor-agnostic studies

Biomarkers & precision oncology

Talk

Sat Oct 24
08:30–08:50

Enhance inclusiveness and patient accrual for clinical trials

Solutions to overcome barriers of access to clinical trials

Talk

Sat Oct 24
08:30–08:50

Presentation by Expert

Sequencing systemic therapies for advanced urothelial cancer

Genitourinary cancers

Chair

Sat Oct 24
08:30–10:00

Solutions to overcome barriers of access to clinical trials

with Netherlands Cancer Institute

Abstract

Sat Oct 24
08:35–08:40

2719RO - FLAURA2: Analysis of on-treatment plasma EGFRm dynamics and associated clinical outcomes in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum–pemetrexed (plat–pem)

Rapid oral 1: NSCLC, metastatic

Lung & thoracic cancers

Talk

Sat Oct 24
08:40–08:50

Welcome from ESMO

EONS Opening session

Nursing & supportive care

Talk

Sat Oct 24
09:10–09:30

Systemic approach

Challenges in the treatment approach of HPV-related head and neck cancers

Sarcoma, CNS, head & neck and rare cancers

Abstract

Sat Oct 24
09:15–09:25

LBA26 - Short-term preoperative durvalumab for stage I TNBC: first results from the phase II UNLOCK 14 - POP-DURVA trial

Proffered paper 2: Breast cancer, early and advanced stage

Breast cancer

Abstract

Sat Oct 24
09:45–09:55

Invited Discussant 1457O, 1458O and 1459O

Proffered Paper: Haematological malignancies

Haematological malignancies

Abstract

Sat Oct 24
10:15–10:20

LBA16 - VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)

Rapid oral 1: Breast cancer, advanced stage

Breast cancer

Talk

Sat Oct 24
11:30–11:37

Table 1

Mentor the Mentor session

Chair

Sat Oct 24
12:00–12:50

ESMO-EACR: What oncologists should know about molecular oncology

with University of Turin, VIB

Biomarkers & precision oncology

Chair

Sat Oct 24
12:00–12:50

What oncologists should know about managing toxicities of novel therapies

with Samsung Medical Center, Hospital Clínic de Barcelona

Nursing & supportive care

Talk

Sat Oct 24
12:15–12:30

Bispecifics

What oncologists should know about managing toxicities of novel therapies

Nursing & supportive care

Talk

Sat Oct 24
12:15–12:30

DNA repair

ESMO-EACR: What oncologists should know about molecular oncology

Biomarkers & precision oncology

Satellite

Sat Oct 24
14:05–14:17

Nuclear Medicine: partner for the Prostate Cancer journey

Novartis - PSMA-targeted RLT in Prostate Cancer: Present and future

Genitourinary cancers

Chair

Sat Oct 24
14:45–16:15

Emerging toxicities induced by antibody-drug conjugates

with Odense University Hospital

Nursing & supportive care

Talk

Sat Oct 24
14:45–15:10

Pulmonary toxicities

Emerging toxicities induced by antibody-drug conjugates

Nursing & supportive care

Talk

Sat Oct 24
15:00–15:15

Pheochromocytoma and paraganglioma

Emerging therapies in endocrine and neuroendocrine neoplasms

Sarcoma, CNS, head & neck and rare cancers

Talk

Sat Oct 24
15:15–15:35

How will new technologies contribute to precision medicine?

YO Lecture: What to expect from precision medicine in the next decade

Biomarkers & precision oncology

Talk

Sat Oct 24
15:20–15:35

View of the interventional radiologist

Management of locally advanced HCC

Gastrointestinal cancers

Talk

Sat Oct 24
15:45–16:05

NUT carcinomas, salivary gland cancers and pulmonary blastomas

Updates on rare thoracic tumours

Lung & thoracic cancers

Talk

Sat Oct 24
15:45–16:05

What to do after optimal neoadjuvant therapy?

Optimising treatment for triple negative early breast cancer

Breast cancer

Chair

Sat Oct 24
16:30–18:15

Presidential Symposium I

Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers

Satellite

Sat Oct 24
18:30–20:00

Ipsen - Treatment decisions that shape the journey in RCC and NETs

with University Hospital Erlangen

Genitourinary cancersSarcoma, CNS, head & neck and rare cancers

Satellite

Sat Oct 24
18:30–18:33

Welcome

Ipsen - Treatment decisions that shape the journey in RCC and NETs

Genitourinary cancersSarcoma, CNS, head & neck and rare cancers

Satellite

Sat Oct 24
18:33–18:43

Sequencing in an ever-changing landscape (RCC and NETs)

Ipsen - Treatment decisions that shape the journey in RCC and NETs · with University Hospital Erlangen

Genitourinary cancersSarcoma, CNS, head & neck and rare cancers

Satellite

Sat Oct 24
18:43–19:23

Navigating the RCC treatment journey

Ipsen - Treatment decisions that shape the journey in RCC and NETs · with City of Hope, Arthur Child Comprehensive Cancer Centre

Genitourinary cancersSarcoma, CNS, head & neck and rare cancers

Talk

Sun Oct 25
08:30–08:35

Presentation of case/condition

Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations

Chair

Sun Oct 25
08:30–10:00

Rapid oral 2: NSCLC, metastatic

with Hospital Universitario 12 de Octubre, Centre Léon Bérard

Lung & thoracic cancers

Chair

Sun Oct 25
08:30–10:00

Rapid oral: Developmental therapeutic

with START Center for Cancer Care, University of Oxford

Chair

Sun Oct 25
08:30–09:45

Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations

with Heidelberg University Hospital

Abstract

Sun Oct 25
08:35–08:40

4245RO - Complementary roles of Liquid Biopsy and Imaging in Assessing Tumor Burden in Metastatic Cancer

Rapid oral 1: Basic science and translational research

Biomarkers & precision oncology

Abstract

Sun Oct 25
08:45–08:57

Invited Discussant 1006RO, LBA33 and 1007RO

Rapid oral: Developmental therapeutic

Talk

Sun Oct 25
08:55–09:15

Implementation science (incl. Federated learning)

Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations

Abstract

Sun Oct 25
08:57–09:02

4246RO - Microbiome Toposcore Dynamics Following Fecal Microbiota Transplantation in Immuno-Oncology: A Multi-Cohort Longitudinal Analysis

Rapid oral 1: Basic science and translational research

Biomarkers & precision oncology

Abstract

Sun Oct 25
09:29–09:44

Invited Discussant 2618RO, 2652RO and 2680RO

Rapid oral 2: NSCLC, metastatic

Lung & thoracic cancers

Chair

Sun Oct 25
10:15–11:45

AI in cancer care: Transforming treatment, navigating challenges

with Memorial Sloan Kettering Cancer Center

Chair

Sun Oct 25
10:15–11:45

ESMO-ASCO: The evolving definition of the modern oncologist

with Dana-Farber Cancer Institute

Chair

Sun Oct 25
10:15–11:45

Emerging new systemic therapies for RCC

with Ghent University Hospital

Genitourinary cancers

Talk

Sun Oct 25
10:15–10:35

Novel HIF2a targeted agents and combination strategies

Emerging new systemic therapies for RCC

Genitourinary cancers

Talk

Sun Oct 25
10:45–11:00

AI for drug development

AI in cancer care: Transforming treatment, navigating challenges

Satellite

Sun Oct 25
13:05–13:15

Building Bridges in the Management of CSCC

Regeneron - Reshaping Adjuvant and Perioperative Strategies in CSCC: Integrating Surgery, Radiation, and Systemic Therapies Through Multidisciplinary Decisions · with George Washington University, Policlinico Universitario Agostino Gemelli, National and Kapodistrian University of Athens +1 more

Melanoma & skin cancers

Satellite

Sun Oct 25
13:10–13:40

Addressing myths in first treatment choice to optimise outcomes and patient wellbeing in mHSPC

Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer · with Cliniques universitaires Saint-Luc

Genitourinary cancers

Satellite

Sun Oct 25
13:15–13:35

Resectable or Not: Navigating the Gray Zones in Advanced CSCC

Melanoma & skin cancers

Satellite

Sun Oct 25
13:35–13:50

Defining High-risk CSCC: Identifying Patients Who Need More

Melanoma & skin cancers

Satellite

Sun Oct 25
13:40–13:45

Audience Q&A: Advanced prostate cancer

Astellas - Why first choice matters: Optimising treatment at the earliest opportunity for patients with advanced prostate or urothelial cancer · with Hospital Clínico San Carlos, Cliniques universitaires Saint-Luc

Genitourinary cancers

Talk

Sun Oct 25
13:45–14:00

Rewriting the patient voice with large language models

Digital health, data and innovation

Satellite

Sun Oct 25
13:50–14:20

Timing and Selection of Systemic Therapy in Resectable CSCC

Melanoma & skin cancers

Satellite

Sun Oct 25
14:20–14:30

Audience Q&A

Melanoma & skin cancers

Chair

Sun Oct 25
14:45–16:25

Proffered paper: Prevention, early detection and intervention

with Memorial Sloan Kettering Cancer Center

Talk

Sun Oct 25
15:10–15:30

Neoadjuvant therapy: A global prescription for cure

More cures in early melanoma

Melanoma & skin cancers

Abstract

Sun Oct 25
15:44–15:49

1538RO - First Interim Safety analysis of GORTEC 2024-03 IDEAL: randomized phase II trial of induction treatment anti–PD-1 pucotenlimab (HX008) plus EGFR-ADC (becotatug vedotin (MRG003) versus EGFR-ADC alone followed by chemoradiotherapy in locally advanced head and neck squamous cell carcinoma

Rapid oral: Head and neck cancer

Sarcoma, CNS, head & neck and rare cancers

Abstract

Sun Oct 25
15:44–15:49

3594RO - Feasibility and reproducibility of PD-L1 assessment within CARE1: a phase III, randomized, biomarker-driven pragmatic trial to optimize first line treatment in patients (pts) with metastatic clear-cell renal cell carcinoma (mRCC)

Rapid oral 2: Genitourinary tumours, renal and urothelial

Genitourinary cancers

Abstract

Sun Oct 25
16:05–16:15

Invited Discussant 3440O and 3441O

Proffered paper: Prevention, early detection and intervention

Talk

Sun Oct 25
16:30–16:55

Individual cancer risk assessment: A critical appraisal

Pillars of personalised cancer prevention: The breast cancer case

Breast cancer

Abstract

Sun Oct 25
16:42–16:54

Invited Discussant LBA5

Presidential Symposium II

Lung & thoracic cancersGastrointestinal cancers

Talk

Mon Oct 26
08:30–08:50

ESMO’s Framework for the evaluation of cancer early detection biomarkers in bodily fluids

Early detection and prevention of cancer

Chair

Mon Oct 26
08:30–10:00

Early detection and prevention of cancer

with Winship Cancer Institute of Emory University

Chair

Mon Oct 26
08:30–10:00

Navigating the wave of new therapies in gynaecologic cancers

with University Hospitals Leuven

Gynaecological cancers

Abstract

Mon Oct 26
08:40–08:50

LBA92 - HOPE: phase III randomized trial of a personalized digital supportive-care pathway (DP) for endocrine therapy (ET) symptoms in early breast cancer (BC)

Proffered paper: Supportive and palliative care

Nursing & supportive care

Talk

Mon Oct 26
09:10–09:30

ESMO guidance on endpoints, study designs, and expected magnitude of clinical benefit for the pharmacological prevention of cancer

Early detection and prevention of cancer

Abstract

Mon Oct 26
09:38–09:50

Invited Discussant 3084O, 3893O and 3894O

Proffered paper: Supportive and palliative care

Nursing & supportive care

Chair

Mon Oct 26
10:15–11:45

Addressing the risk of second primary cancers

with Queen Elizabeth Hospital

Nursing & supportive care

Chair

Mon Oct 26
13:00–14:30

ESMO Fellowship Programme: Educational opportunities for young oncologists

with Institut Strauss, Hospital Clínic de Barcelona

Talk

Mon Oct 26
13:25–13:35

From emerging oncologist to independent investigator: A personal journey

ESMO Fellowship Programme: Educational opportunities for young oncologists

Chair

Mon Oct 26
14:45–15:45

ESMO-CSCO: Navigating the development pathways of cancer therapeutics -From China to the world

with Guangdong Provincial People's Hospital

Chair

Mon Oct 26
14:45–16:15

Proffered paper: Non-metastatic NSCLC and other thoracic malignancies

with Erasmus MC

Lung & thoracic cancers

Abstract

Mon Oct 26
14:55–15:00

3137RO - Safety and Efficacy of INCB161734, a Novel Oral KRAS G12D Inhibitor, in Combination with Chemotherapy in Patients (pts) with Advanced/Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Rapid oral 2: Gastrointestinal tumour, upper digestive

Gastrointestinal cancers

Talk

Mon Oct 26
15:10–15:25

How to simplify the algorithm of treatment of rare endocrine tumors

Endocrine tumours at a glance

Sarcoma, CNS, head & neck and rare cancers

Abstract

Mon Oct 26
15:12–15:17

3884RO - Lung Cancer Prevention in Patients with Severe Mental Illness: A Real-World Cohort Experience from the INTERCEPTION-Lung Precision Prevention Program

Rapid oral: Prevention, early detection and intervention

Abstract

Mon Oct 26
15:53–16:05

Invited Discussant LBA64, 2519O and 2511O

Proffered paper: Non-metastatic NSCLC and other thoracic malignancies

Lung & thoracic cancers

Chair

Mon Oct 26
16:30–17:45

Alleviating total suffering in patients with advanced cancer: It’s time for interdisciplinary interventions

with Aston University

Nursing & supportive care

Chair

Mon Oct 26
16:30–18:00

IO-based systemic therapy in head and neck cancers

with National Centre for Oncological Hadrontherapy (CNAO)

Sarcoma, CNS, head & neck and rare cancers

Talk

Mon Oct 26
16:30–16:35

Presentation of case/condition

Alleviating total suffering in patients with advanced cancer: It’s time for interdisciplinary interventions

Nursing & supportive care

Abstract

Mon Oct 26
16:42–16:54

Invited Discussant LBA9

Presidential Symposium III

Gynaecological cancersSarcoma, CNS, head & neck and rare cancers

Chair

Tue Oct 27
09:00–13:00

Scientific Congress Highlights 2

with Hospital Clínic de Barcelona

Talk

Tue Oct 27
12:40–13:00

Prevention, early detection and intervention

Scientific Congress Highlights 2

Instantly find 20 buyers from organizations at ESMO 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

The ESMO Congress is the European Society for Medical Oncology’s annual meeting, held October 23–27, 2026 at IFEMA in Madrid — Europe’s largest oncology congress, with about 37,000 participants. It brings together medical oncologists, cancer researchers, oncology nurses and the pharma, biotech and diagnostics companies that serve them, across educational sessions, proffered-paper and rapid-oral abstract sessions, special symposia, industry satellite symposia and an exhibition.

What is in this guide?

Every organization we can place at ESMO 2026: the institutions of 1,135 faculty, chairs and presenting authors from the Final Programme (1,733 sessions and talks), plus the 235 exhibitors and 6 more industry satellite sponsors — 736 organizations in one list. People appear as a count, never by name. Poster authors’ institutions are published on October 19 and will be added then.

How are organizations typed?

By the role an organization plays in cancer care and oncology drug development: drug developers (large pharma and biotech), diagnostics and tools, CROs, medical education and other services, cancer centres and hospitals, universities and institutes, and societies and non-profits. The tumour-type filters come from ESMO’s own tumour-site tags on each session, and otherwise from the session’s title.

How current is it?

Pulled from the ESMO Congress 2026 Final Programme (updated September 29, with the late-breaking abstracts and their presenting authors), ESMO’s public session data and the Exhibitor List on September 29, 2026. Poster authors are not yet public.

Organizations with their own page

396 organizations — every exhibitor and every organization with 3 or more presentations.

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction

Instantly find 20 buyers from organizations at ESMO 2026

What conference is this?

What is in this guide?

How are organizations typed?

How current is it?

Browse ESMO 2026 by

Organizations with their own page